ARIA‐suggested drugs for allergic rhinitis: what impact on quality of life? A GA²LEN Review

Abstract

Allergic diseases constitute a global health problem, as they have an increasing economic and social impact and, especially, they can deeply interfere with the patients’ daily life, being a cause of physical and emotional discomfort. This is why the health‐related quality‐of‐life (HRQoL) has become increasingly important in health care research; in fact, the assessment of the impact the disease and its treatment have on patients, provides a more comprehensive approach in outcome evaluation. Numerous validated questionnaires are available and many studies have been performed evaluating HRQoL in people affected by allergic rhinitis (AR), thus testifying a great interest in this topic. The aims of the present review are: to examine the scientific literature of the last 3 years dealing with the impact of AR treatments suggested by allergic rhinitis and its impact on asthma guidelines on patients’ QoL, and to identify the unexplored or not‐fully‐investigated areas concerning this issue.

Influence of comorbid conditions on asthma

“…However, it was surprising to note an increase in symptoms of rhinitis in a large population of severe allergic asthmatics treated with omalizumab compared with placebo [29]. Although there is still some controversy about the benefits of adequately treating rhinitis for asthma outcomes, there is evidence that this does improve asthma patients' disease control and quality of life [17,[30][31][32][33][34]. In asthmatic patients with allergic rhinitis, PRICE et al [35] suggested that combined treatment with montelukast and budesonide provided significantly greater efficacy in reducing airflow obstruction compared with doubling the dose of budesonide, possibly through an effect of the former on both the nose and lower airways.…”

Efecto de la rinitis y el asma en el ausentismo y rendimiento laboral y escolar en una población del trópico latinoamericano

“…Aunque en muchos países parte de este gasto es asumido por el tercer pagador (sistema de salud), todas las evaluaciones económicas coinciden en que el gasto es mayor para el paciente, porque es quien asume los costos indirectos de la enfermedad (ausentismo laboral o escolar del paciente y de su grupo social), que según algunos estudios representa la mayor parte de los gastos asociados con la rinitis y el asma. 17 Los resultados de este estudio indican que el tratamiento farmacológico adecuado puede lle- var a un mejor control sintomático; no obstante, también observamos que aunque la mayoría de los pacientes tiene acceso a este tratamiento, la tasa de apego es muy baja, con lo que disminuye su efecto clínico, por lo que se necesitan campañas de promoción y prevención que permitan mayor concientización del problema al paciente.…”

An expert survey for developing pattern diagnosis instrument of persistent allergic rhinitis

“…질에 대한 영향과 중증도 등을 평가할 수 있는 도구 개발 연구들은 지속적으로 진행되어 왔으며 [4][5][6] , 국내 에서도 박 등이 국외에서 개발된 삶의 질 평가 설문 지를 국내에 맞게 변형 개발하여 보고하였고 7) , 진 등 Table 2). 2), 6), 7), 13), 14), 22), 23) 2), 6), 22), 23) 50% …”